TOPMed Omics of Cardiovascular Disease in Diabetes
糖尿病心血管疾病的 TOPMed 组学
基本信息
- 批准号:10425415
- 负责人:
- 金额:$ 79.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2024-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAgeAllelesAtherosclerosisAutomobile DrivingBiologicalBiological MarkersBiologyBloodCardiovascular DiseasesCarotid Artery PlaquesCessation of lifeClinicalCodeCohort StudiesCoronary heart diseaseDNA MethylationDataDiabetes MellitusDimensionsEpidemicEtiologyEventFoundationsGeneticGenetic TranscriptionGenetic VariationGenomicsGoalsHealthHealth systemHeart DiseasesHematological DiseaseIndividualInsulin ResistanceInvestigationKnowledgeLeadLinkLongitudinal cohortLung diseasesMeasuresMedialMendelian randomizationMetabolicMetabolic ControlMethylationNational Heart, Lung, and Blood InstituteNetwork-basedNon-Insulin-Dependent Diabetes MellitusPathway interactionsPersonsProteomicsResourcesRiskRisk FactorsScourgeSeriesStrokeTestingThickTissuesTrans-Omics for Precision MedicineTranslationsVariantWhole BloodWomanaptameratherogenesisbasebiobankcohortcoronary artery calciumcostdiabeticdimensional analysisdisabilityendothelial dysfunctionexperimental studyfollow-upgenetic analysisgenomic locushigh dimensionalityinsightliquid chromatography mass spectroscopymenmetabolomicsmethylomicsmultidisciplinarymultiple omicsnetwork modelsnon-diabeticnovelnovel strategiespreventproteomic signaturerare variantstemtranscriptome sequencingtranscriptomicswhole genome
项目摘要
Project Summary/Abstract
Blood omic biomarkers, including whole genome sequence (WGS), whole blood methylation (measured by
sequencing or microarrays), transcription (using RNA-seq), proteomics (SomaLogic aptamers) and
metabolomics (liquid chromatography/mass spectroscopy) have identified novel pathways to cardiovascular
disease (CVD: coronary heart disease (CHD) and stroke; subclinical atherosclerosis: elevated coronary
artery calcium (CAC), and carotid plaque and intimal-medial thickness (cIMT)). Individually, but especially
together in multidimensional network frameworks, omics data in the NHLBI Trans-Omics for Precision
Medicine (TOPMed) study are poised to address major problems in biomedicine. In this application we focus
on multi-omic investigation of CVD in type 2 diabetes (T2D). T2D is a growing scourge worldwide, driving a
major global epidemic of CVD. CVD events occur over twice as frequently in people with T2D. The reasons
for this persistent excess risk remain unknown but likely involve perturbations across multiple omic
dimensions, from genetic variation to networks that link insulin resistance, endothelial dysfunction and
atherogenesis. Elucidation of the biology underlying CVD in T2D offers a clear opportunity to stem the global
tide of CVD. We propose three Aims. In Aim 1, we will analyze genetic variation from WGS data from 23,903
people with T2D from 5 ancestry groups from 28 cohorts (11 longitudinal) of men and women of diverse
ages, including 15 with prevalent CVD and 11 with measures of subclinical atherosclerosis. We have linked
WGS data to diverse annotation resources (e.g. ENCODE). We have clinical covariates including age of T2D
onset and level of metabolic control, and longitudinal follow-up for incident CVD events. Analyses of common
and rare variation will elucidate known candidate CVD-T2D loci and lead to new discovery. Replication is
available in >220,000 T2D individuals of diverse ancestry from 5 biobanks. Validated variants will be used in
Mendelian Randomization tests of causality and polygenic scores for prediction. In Aim 2, we will analyze
blood omic biomarkers individually, guided by Aim 1 genomic associations with CVD in T2D. TOPMed has
omics data on a subset of 2,507 sequenced people with T2D from 4 ancestry groups, with more planned. A
clear understanding of the association of each omic dimension with CVD in T2D is useful to understand that
dimension as a unique exposure for CVD in T2D. Interpretation of Aim 2 omic associations will first be
informed by WGS association from Aim 1, then by combining WGS information with all four omic dimensions
(Aim 3). We will use both Aim 2-association-based and agnostic multidimensional-based approaches to build
multilevel network models of the pathobiology of CVD in T2D. “TOPMed Omics of Cardiovascular Disease in
Diabetes” is highly responsive to NOT-HL-19-676, leveraging TOPMed resources to elucidate the pathway
biology of heart, lung and blood diseases. Our team, with a proven track record in omics discovery, aims to
find new approaches to prevent and treat CVD in T2D.
项目总结/摘要
血液组学生物标志物,包括全基因组序列(WGS)、全血甲基化(通过
测序或微阵列),转录(使用RNA-seq),蛋白质组学(SomaLogic适体)和
代谢组学(液相色谱/质谱)已经确定了心血管疾病的新途径,
疾病(CVD:冠心病(CHD)和卒中;亚临床动脉粥样硬化:冠状动脉粥样硬化
动脉钙(CAC)和颈动脉斑块和内膜-中层厚度(cIMT))。个别的,但特别是
在多维网络框架中,NHLBI Trans-Omics for Precision中的组学数据
医学(TOPMed)研究准备解决生物医学中的主要问题。在这个应用程序中,我们专注于
2型糖尿病(T2 D)CVD的多组学研究。T2 D是全球范围内日益严重的祸害,
CVD的全球流行病。CVD事件在T2 D患者中的发生频率是T2 D患者的两倍多。的原因
对于这种持续的过度风险仍然未知,但可能涉及多个omic的扰动
从遗传变异到连接胰岛素抵抗、内皮功能障碍和
动脉粥样硬化阐明T2 D中CVD的生物学基础提供了一个明确的机会,可以阻止全球性
心血管疾病的浪潮。我们提出三个目标。在目标1中,我们将分析来自23,903份WGS数据的遗传变异,
来自5个祖先群体的T2 D患者,来自28个队列(11个纵向队列),
年龄,包括15例普遍CVD和11例亚临床动脉粥样硬化的措施。我们联系了
WGS数据到不同的注释资源(例如ENCODE)。我们有临床协变量,包括T2 D的年龄
代谢控制的开始和水平,以及对意外CVD事件的纵向随访。常见问题分析
和罕见的变异将阐明已知的候选CVD-T2 D基因座,并导致新的发现。复制是
在来自5个生物库的> 220,000个不同血统的T2 D个体中可用。经确认的变体将用于
因果关系和多基因评分的孟德尔随机化检验用于预测。在第二章中,我们将分析
血液组学生物标志物,由目标1与T2 D中CVD的基因组关联指导。TOPMed具有
来自4个祖先群体的2,507名测序T2 D患者的子集的组学数据,计划更多。一
清楚地了解T2 D中每个组学维度与CVD的关联有助于理解,
尺寸作为T2 D中CVD的独特暴露。对目标2组学关联的解释将首先是
由目标1的WGS关联告知,然后通过将WGS信息与所有四个组学维度相结合,
(Aim 3)。我们将使用Aim 2-基于关联和基于不可知的多维方法来构建
T2 D中CVD病理生物学的多级网络模型。“TOPMed心血管疾病组学,
糖尿病”是高度响应NOT-HL-19-676,利用TOPMed资源阐明途径
心脏、肺和血液疾病的生物学。我们的团队在组学发现方面有着良好的记录,旨在
寻找新的方法来预防和治疗2型糖尿病心血管疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JAMES B MEIGS其他文献
JAMES B MEIGS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JAMES B MEIGS', 18)}}的其他基金
TOPMed Omics of Cardiovascular Disease in Diabetes
糖尿病心血管疾病的 TOPMed 组学
- 批准号:
10200144 - 财政年份:2020
- 资助金额:
$ 79.71万 - 项目类别:
TOPMed Omics of Cardiovascular Disease in Diabetes
糖尿病心血管疾病的 TOPMed 组学
- 批准号:
10664855 - 财政年份:2020
- 资助金额:
$ 79.71万 - 项目类别:
International Diabetes Epidemiology Group 2009
2009 年国际糖尿病流行病学小组
- 批准号:
7800179 - 财政年份:2009
- 资助金额:
$ 79.71万 - 项目类别:
Common Genetic Variation and Quantitative Diabetes Traits
常见的遗传变异和定量糖尿病特征
- 批准号:
8486419 - 财政年份:2008
- 资助金额:
$ 79.71万 - 项目类别:
Common Genetic Variation and Quantitative Diabetes Traits
常见的遗传变异和定量糖尿病特征
- 批准号:
8198807 - 财政年份:2008
- 资助金额:
$ 79.71万 - 项目类别:
Common Genetic Variation and Quantitative Diabetes Traits
常见的遗传变异和定量糖尿病特征
- 批准号:
8663239 - 财政年份:2008
- 资助金额:
$ 79.71万 - 项目类别:
Common Genetic Variation and Diabetes Traits in Framingham
弗雷明汉的常见遗传变异和糖尿病特征
- 批准号:
7577497 - 财政年份:2008
- 资助金额:
$ 79.71万 - 项目类别:
Common Genetic Variation and Quantitative Diabetes Traits
常见的遗传变异和定量糖尿病特征
- 批准号:
8293035 - 财政年份:2008
- 资助金额:
$ 79.71万 - 项目类别:
Common Genetic Variation and Quantitative Diabetes Traits
常见的遗传变异和定量糖尿病特征
- 批准号:
8705791 - 财政年份:2008
- 资助金额:
$ 79.71万 - 项目类别:
Common Genetic Variation and Diabetes Traits in Framingham
弗雷明汉的常见遗传变异和糖尿病特征
- 批准号:
7782671 - 财政年份:2008
- 资助金额:
$ 79.71万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 79.71万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 79.71万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 79.71万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 79.71万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 79.71万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 79.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 79.71万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 79.71万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 79.71万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 79.71万 - 项目类别:
Research Grant